Skip to content
value.today
Total raised
$10 M
2 rounds on record
Latest round
$5 M
Dec 2018
First round on record
Jun 2017
Today
Went public
See the company page

Prima BioMed Ltd is listed today as Immutep Ltd: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Prima BioMed Ltd
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2018$5 MNo. 2$2 to $10 million

Prima BioMed Ltd: Raise no. 2, Dec 2018

Investors in this round

2 investors had bought by the notice of Dec 21, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Australia

People named in the notice

  • Deanne John Miller · Executive Officer
  • Frederic John Triebel · Executive Officer
  • Marc Voigt · Executive Officer, Director
  • Grant Chamberlain · Director
  • Pete John Meyers · Director
  • Russell John Howard · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents total proceeds from ADSs sold in a concurrent registered offering and warrants sold in the private placement reported by this Form D.”

Signed by Deanne Miller, Chief Operating Officer, General Counsel & Company Secretary. Source: SEC Form D, newest notice filed Dec 21, 2018. Read the notice at the SEC.

optionsSEC
Jun 2017$5 MNo. 1$2 to $10 million

Prima BioMed Ltd: Raise no. 1, Jun 2017

Investors in this round

6 investors had bought by the notice of Jul 14, 2017: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$236,605
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Australia

People named in the notice

  • Deanne Miller · Executive Officer, Director
  • Frederic Triebel · Executive Officer, Director
  • Marc Voigt · Executive Officer, Director
  • Albert Wong · Director
  • Lucy Turnbull · Director
  • Peter Meyers · Director
  • Russell Howard · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in IL, NJ, NY

Remarks in the notice

  • On fees: “Represents total placement agent fee for concurrent registered offering of ADSs and for warrants issued under Reg D. Excludes $75,000 expense reimbursement.”
  • On the amounts: “Represents total proceeds from ADSs sold in a concurrent registered offering and warrants sold in the private placement reported by this Form D.”

Signed by Deanne Miller, Chief Operating Officer, General Counsel & Secretary. Source: SEC Form D, newest notice filed Jul 14, 2017. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Prima BioMed Ltd chose not to state its revenue in its newest notice of a funding round (Dec 2018).

    SEC Form D · Dec 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2018

That is all the official record says: Prima BioMed Ltd has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products#

  • etilagimod alpha

From the company page of Immutep Ltd.

Services#

No services of Prima BioMed Ltd are on record.

Investors#

No investor of Prima BioMed Ltd is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 6 investors.

Largest shareholders today

Institutions holding Immutep Ltd shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Prima BioMed Ltd
NameRoleNamed in
Deanne John MillerExecutive officerDec 2018
Frederic John TriebelExecutive officerDec 2018
Marc VoigtExecutive officerDec 2018
Deanne MillerExecutive officerJul 2017
Frederic TriebelExecutive officerJul 2017
Grant ChamberlainDirectorDec 2018
Marc VoigtDirectorDec 2018
Pete John MeyersDirectorDec 2018
Russell John HowardDirectorDec 2018
Albert WongDirectorJul 2017
Deanne MillerDirectorJul 2017
Frederic TriebelDirectorJul 2017
Lucy TurnbullDirectorJul 2017
Peter MeyersDirectorJul 2017
Russell HowardDirectorJul 2017

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.